IP Library Granted Patent US 10,272,119
Granted Patent B2
US 10,272,119 · App. 15/636,227 · Granted Apr 30, 2019

Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition

Inventors: Scheffer Tseng (Pinecrest, FL); Hua He (Miami, FL); Wei Li (Shenzhen, CN)
Assignee: TISSUETECH, INC.
A61K35/50A61K8/982A61K9/0014A61K9/0048A61K9/0053A61K9/06A61K9/08A61K9/19A61K31/738A61K35/48A61K38/1709A61K38/39A61K38/4886A61L15/40A61L15/44A61Q19/00C07K14/4702C07K14/4718C07K14/78C07K14/8114A61K2800/74A61L2300/412A61L2300/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,272,119
App. No.
15/636,227
Granted
Apr 30, 2019
Kind
B2
Abstract

Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.

Claims (13)

1. A method of promoting wound healing in an individual in need thereof, comprising administering to a wound a composition comprising ground or pulverized amniotic membrane isloated from a frozen or previously frozen placental material.

2. The method of claim 1 , wherein the ground or pulverized amniotic membrane is in the form of a dry powder.

3. The method of claim 1 , wherein the ground or pulverized amniotic membrane is in the form of a homogenate, liquid, or suspension.

4. The method of claim 1 , wherein the placental material is placenta.

5. The method of claim 1 , wherein the amniotic membrane is human amniotic membrane, bovine amniotic membrane, or porcine amniotic membrane.

6. The method of claim 1 , wherein the composition further comprises collagen, fibrin, hyaluronic acid, or a combination thereof.

7. The method of claim 1 , wherein the composition further comprises a pharmaceutically-acceptable diluent, excipient, carrier, or combination thereof.

8. The method of claim 7 , wherein the composition is a non-solid dosage form.

9. The method of claim 7 , wherein the composition is formulated as a solution, drops, suspension, aerosol, paste, ointment, oil, emulsion, cream, lotion, gel, a coated bandage, a patch, sticks, balms, or shampoo, or combination thereof.

10. The method of claim 7 , wherein the composition is a solid dosage form.

11. The method of claim 7 , wherein the composition is a dry powder form.

12. The method of claim 7 , wherein the composition is formulated for ophthalmic administration, systemic administration, or topical administration.

13. The method of claim 7 , wherein the composition is formulated for controlled release.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FUNDING IV TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0200 →
SECURITY INTEREST Recorded Jun 7, 2024
From: BIOTISSUE HOLDINGS INC.; BIOTISSUE OCULAR INC.; BIOTISSUE SURGICAL INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 067666/0235 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FINANCIAL TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0165 →
CHANGE OF NAME Recorded May 22, 2023
From: TISSUETECH, INC.
To: BIOTISSUE HOLDINGS INC.
Reel/Frame 063713/0329 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - TERM LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 060116/0413 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - REVOLVING LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 060116/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2017
From: BIO-TISSUE, INC.
To: TISSUETECH, INC.
Reel/Frame 042854/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2017
From: TSENG, SCHEFFER; HE, HUA; LI, WEI
To: BIO-TISSUE, INC.
Reel/Frame 042854/0041 →
Continuity (6)
Continuation 14848148 · Sep 8, 2015
Continuation 13802359 · Mar 13, 2013
Continuation 13453765 · Apr 23, 2012
Continuation 11528902 · Sep 27, 2006
Provisional Application 60720760 · Sep 27, 2005
Related Publication 20170326182A1 · Nov 16, 2017
Cited By (3)
US 12,551,509 US 12,551,510 US 12,558,379